4.7 Article

Lectin-like Oxidized LDL Receptor 1 Is Involved in CRP-Mediated Complement Activation

Journal

CLINICAL CHEMISTRY
Volume 57, Issue 10, Pages 1398-1405

Publisher

AMER ASSOC CLINICAL CHEMISTRY
DOI: 10.1373/clinchem.2011.168625

Keywords

-

Funding

  1. Ministry of Education, Culture, Sports, Science and Technology of Japan
  2. Ministry of Health, Labour and Welfare of Japan
  3. National Institute of Biomedical Innovation
  4. Japan Science and Technology Agency
  5. New Energy and Industrial Technology Development Organization
  6. Japan Vascular Disease Research Foundation
  7. Institute of Seizon and Life Sciences
  8. Grants-in-Aid for Scientific Research [22390051] Funding Source: KAKEN

Ask authors/readers for more resources

BACKGROUND: C-reactive protein (CRP) is purported to be a risk factor that acts independently of LDL cholesterol in predicting all-cause mortality in patients with ischemic heart disease. Lectin-like oxidized LDL receptor 1 (LOX-1) impairs endothelial function and exacerbates myocardial injury. We recently demonstrated that CRP increased vascular permeability through direct binding to LOX-1. Here we examined, using a hypertensive rat model, whether LOX-1 is involved in CRP-induced complement activation. METHODS AND RESULTS: In the cultured LOX-1-expressing cell line hLOX-1-CHO, CRP increased complement activation, but did not do so in native CHO cells. Depleting C1q from serum abolished CRP-induced complement activation. Incubation of CRP with serum on immobilized recombinant LOX-1 similarly showed that CRP activated C1q-requiring classical complement pathway in a LOX-1-dependent manner. Interestingly, the interaction between CRP and LOX-1 was dependent on Ca(2+) ion and competed with phosphocholine, suggesting that LOX-1 bound to the B-face of CRP with a phosphocholine-binding domain. This was in contrast to Fc gamma receptors, to which CRP bound in A-face with complement-binding domain. In vivo, intradermal injection of CRP to hypertensive SHRSP rats induced complement activation detected by C3d deposition and leukocyte infiltration around the injected area. Anti-LOX-1 antibody reduced the extent of complement activation and leukocyte infiltration. CONCLUSIONS: LOX-1 appears to be involved in CRP-induced complement activation, and thus may serve to locate the site of CRP-induced complement activation and inflammation. (C) 2011 American Association for Clinical Chemistry

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available